AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
AAPL   382.73 (+0.36%)
MSFT   214.32 (+0.70%)
FB   244.50 (+0.38%)
GOOGL   1,518.66 (+1.00%)
AMZN   3,182.63 (+3.29%)
NVDA   420.36 (+2.87%)
CGC   16.02 (-1.90%)
BABA   261.58 (+1.51%)
MU   49.98 (+0.54%)
GE   6.58 (-4.08%)
TSLA   1,394.28 (+2.08%)
AMD   57.26 (+7.17%)
T   29.54 (-3.02%)
ACB   11.77 (-3.21%)
F   5.84 (-4.11%)
GILD   74.71 (-1.19%)
DIS   116.81 (+0.13%)
BAC   22.77 (-1.43%)
NFLX   507.76 (+0.99%)
BA   173.28 (-3.78%)
Log in

NASDAQ:RTRXRetrophin Stock Price, Forecast & News

$20.14
-0.68 (-3.27 %)
(As of 07/9/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.00
Now: $20.14
$21.00
50-Day Range
$14.51
MA: $17.18
$20.89
52-Week Range
$8.98
Now: $20.14
$21.91
Volume291,830 shs
Average Volume461,749 shs
Market Capitalization$869.16 million
P/E RatioN/A
Dividend YieldN/A
Beta0.86
Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Fosmetpantotenate, a novel small molecule that is in Phase III clinical trial to treat pantothenate kinase-associated neurodegeneration; Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy; CNSA-001, an orally bioavailable proprietary form of sepiapterin that is in phase II clinical trial for the treatment of phenylketonuria; and liquid ursodeoxycholic acid, a liquid formulation of ursodeoxycholic acid for the treatment of primary biliary cholangitis. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.
Read More
Retrophin logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.4Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.27 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:RTRX
CUSIPN/A
Phone760-260-8600

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$175.34 million
Book Value$5.15 per share

Profitability

Net Income$-146,430,000.00

Miscellaneous

Employees214
Market Cap$869.16 million
Next Earnings Date8/4/2020 (Estimated)
OptionableOptionable

Receive RTRX News and Ratings via Email

Sign-up to receive the latest news and ratings for RTRX and its competitors with MarketBeat's FREE daily newsletter.

Retrophin (NASDAQ:RTRX) Frequently Asked Questions

How has Retrophin's stock been impacted by COVID-19 (Coronavirus)?

Retrophin's stock was trading at $14.79 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RTRX shares have increased by 36.2% and is now trading at $20.14. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Retrophin?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Retrophin in the last year. There are currently 1 hold rating and 7 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Retrophin.

When is Retrophin's next earnings date?

Retrophin is scheduled to release its next quarterly earnings announcement on Tuesday, August 4th 2020. View our earnings forecast for Retrophin.

How were Retrophin's earnings last quarter?

Retrophin Inc (NASDAQ:RTRX) announced its earnings results on Monday, May, 11th. The biopharmaceutical company reported $0.02 EPS for the quarter, beating analysts' consensus estimates of ($0.68) by $0.70. The biopharmaceutical company earned $47.77 million during the quarter, compared to analyst estimates of $43.14 million. Retrophin had a negative return on equity of 43.15% and a negative net margin of 57.01%. View Retrophin's earnings history.

What price target have analysts set for RTRX?

8 equities research analysts have issued 12-month target prices for Retrophin's stock. Their forecasts range from $19.00 to $34.00. On average, they expect Retrophin's share price to reach $28.00 in the next year. This suggests a possible upside of 39.0% from the stock's current price. View analysts' price targets for Retrophin.

Has Retrophin been receiving favorable news coverage?

News coverage about RTRX stock has been trending negative this week, according to InfoTrie. The research firm identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Retrophin earned a news sentiment score of -2.3 on InfoTrie's scale. They also gave media coverage about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days. View the latest news about Retrophin.

Who are some of Retrophin's key competitors?

What other stocks do shareholders of Retrophin own?

Who are Retrophin's key executives?

Retrophin's management team includes the following people:
  • Ms. Laura M. Clague CPA, CFO & Sr. VP (Age 60)
  • Mr. Neil F. McFarlane, Chief Operating Officer (Age 46)
  • Dr. William E. Rote, Sr. VP and Head of R&D (Age 56)
  • Dr. Noah L. Rosenberg, Chief Medical Officer (Age 52)
  • Dr. Eric M. Dube Ph.D., Pres, CEO & Director (Age 46)

What is Retrophin's stock symbol?

Retrophin trades on the NASDAQ under the ticker symbol "RTRX."

How do I buy shares of Retrophin?

Shares of RTRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Retrophin's stock price today?

One share of RTRX stock can currently be purchased for approximately $20.14.

How big of a company is Retrophin?

Retrophin has a market capitalization of $869.16 million and generates $175.34 million in revenue each year. The biopharmaceutical company earns $-146,430,000.00 in net income (profit) each year or ($3.46) on an earnings per share basis. Retrophin employs 214 workers across the globe.

What is Retrophin's official website?

The official website for Retrophin is www.retrophin.com.

How can I contact Retrophin?

Retrophin's mailing address is 3721 VALLEY CENTRE DR. SUITE 200, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at 760-260-8600 or via email at [email protected]

This page was last updated on 7/9/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.